{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=89", "query": { "intervention": "Continuous Dose", "page": 89 }, "page_size": 10 }, "pagination": { "page": 89, "page_size": 10, "total_count": 5326, "total_pages": 533, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=90&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=88&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T09:08:57.383Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02218164", "title": "Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Skin", "Carcinoma, Squamous Cell" ], "interventions": [ { "name": "Pegylated Interferon alpha-2b", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-08-12", "completion_date": "2018-06-25", "has_results": true, "last_update_posted_date": "2022-10-07", "last_synced_at": "2026-11-14T09:08:57.383Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02218164" }, { "nct_id": "NCT03944447", "title": "Outcomes Mandate National Integration With Cannabis as Medicine", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Pain", "Chronic Pain Syndrome", "Chronic Pain Due to Injury", "Chronic Pain Due to Trauma", "Fibromyalgia", "Seizures", "Hepatitis C", "Cancer", "Crohn Disease", "HIV/AIDS", "Multiple Sclerosis", "Traumatic Brain Injury", "Sickle Cell Disease", "Post Traumatic Stress Disorder", "Tourette Syndrome", "Ulcerative Colitis", "Glaucoma", "Epilepsy", "Inflammatory Bowel Diseases", "Parkinson Disease", "Amyotrophic Lateral Sclerosis", "Chronic Traumatic Encephalopathy", "Anxiety", "Depression", "Insomnia", "Autism", "Opioid-use Disorder", "Bipolar Disorder", "Covid19", "SARS-CoV Infection", "COVID-19", "Corona Virus Infection", "Coronavirus" ], "interventions": [ { "name": "Cannabis, Medical", "type": "DRUG" }, { "name": "RYAH-Medtech Inhaler", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "OMNI Medical Services, LLC", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 200000, "start_date": "2018-12-01", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2022-06-02", "last_synced_at": "2026-11-14T09:08:57.383Z", "location_count": 17, "location_summary": "Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03944447" }, { "nct_id": "NCT00951158", "title": "A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Conjugated Linoleic Acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "Conjugated Linoleic Acid", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2010-03", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2015-05-12", "last_synced_at": "2026-11-14T09:08:57.383Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00951158" }, { "nct_id": "NCT02766465", "title": "Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "r-ATG", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplant", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Standard of Care", "type": "PROCEDURE" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 138, "start_date": "2017-03-16", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-11-14T09:08:57.383Z", "location_count": 35, "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02766465" }, { "nct_id": "NCT00004467", "title": "Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Liver Failure" ], "interventions": [ { "name": "N-acetylcysteine (NAC)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 173, "start_date": "1998-06", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2017-10-13", "last_synced_at": "2026-11-14T09:08:57.383Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004467" }, { "nct_id": "NCT00601705", "title": "Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2008-01-05", "completion_date": "2015-01-23", "has_results": true, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-11-14T09:08:57.383Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00601705" }, { "nct_id": "NCT05163314", "title": "A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dravet Syndrome (DS)", "Lennox Gastaut Syndrome (LGS)" ], "interventions": [ { "name": "Soticlestat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "56 Years", "sex": "ALL", "summary": "2 Years to 56 Years" }, "enrollment_count": 352, "start_date": "2022-03-04", "completion_date": "2025-09-24", "has_results": true, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-11-14T09:08:57.383Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05163314" }, { "nct_id": "NCT00758043", "title": "A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "telaprevir", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 540, "start_date": "2008-10", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2021-03-26", "last_synced_at": "2026-11-14T09:08:57.383Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00758043" }, { "nct_id": "NCT03656926", "title": "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchiolitis Obliterans", "Chronic Rejection of Lung Transplant", "Lung Transplant Rejection", "Lung Transplant; Complications", "Lung Transplant Failure and Rejection", "Chronic Lung Allograft Dysfunction" ], "interventions": [ { "name": "Liposomal Cyclosporine A", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zambon SpA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2019-03-26", "completion_date": "2024-03-12", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-11-14T09:08:57.383Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656926" }, { "nct_id": "NCT03709108", "title": "Safety and Feasibility of an Insulin Sensitivity-Informed Bolus Calculator in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "SI-Informed Bolus Calculator", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2018-11-19", "completion_date": "2019-03-31", "has_results": false, "last_update_posted_date": "2024-07-17", "last_synced_at": "2026-11-14T09:08:57.383Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03709108" } ] }